Status:
COMPLETED
The Nordic Bifurcation Study III
Lead Sponsor:
Evald Hoej Christiansen
Collaborating Sponsors:
Johnson & Johnson
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
Phase:
NA
Brief Summary
Should we, or should we not, perform dilatation of the side branch through the main vessel stent, if there is acceptable blood flow in the side branch?
Detailed Description
Design: * Randomised open multicentre trial Patients: * Number 477 Randomisation: * Treatment strategy kissing or no kissing balloon post-dilatation Primary end point: * Combined end point of: ...
Eligibility Criteria
Inclusion
- Stable or unstable angina pectoris. -Bifurcation lesion of "LAD/diagonal", "Cx/obtuse marginal", "RCA--
- PDA/posterola¬te¬ral branch" or "LM/Cx/LAD".
- Diameter of main vessel by visual estimate \> 2.5 mm.
- Diameter of side branch by visual estimate \> 2.25 mm.
- Signed informed consent
Exclusion
- Age \< 18 years.
- ST-elevation infarction within 24 hours.
- Expected survival \< 1 year.
- S-creatinine \> 200 µmol/l.
- Allergy to Aspirin, Clopidogrel or Ticlopidine.
- Allergy to Sirolimus.
Key Trial Info
Start Date :
April 2 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2021
Estimated Enrollment :
477 Patients enrolled
Trial Details
Trial ID
NCT00914199
Start Date
April 2 2007
End Date
November 1 2021
Last Update
January 2 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aarhus University Hospital Skejby
Aarhus, Denmark, 8200